From the American College of Rheumatology
In a significant and dangerous departure from previous policy, the Centers for Medicare and Medicaid Services (CMS) will begin adjusting Part B drug reimbursements to physicians based on their performance in the Merit-based Incentive Payment System (MIPS) beginning in 2018. Unless lawmakers act swiftly to reverse this policy, some rheumatology providers will see significant payment cuts and may be forced to stop administering vital Part B drug therapies.
We need Congress to act immediately to reverse this policy and ensure Medicare patients have access to the Part B drug treatments and in-office services they need. Please write your lawmakers and ask them to take immediate legislative action to prevent payment adjustments from being applied to Part B drug payments to physicians under MIPS.